Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Review ArticleReview Article
Open Access

Viral G Protein–Coupled Receptors: Attractive Targets for Herpesvirus-Associated Diseases

Timo W. M. De Groof, Elizabeth G. Elder, Marco Siderius, Raimond Heukers, John H. Sinclair and Martine J. Smit
Gunnar Schulte, ASSOCIATE EDITOR
Pharmacological Reviews April 2021, 73 (2) 828-846; DOI: https://doi.org/10.1124/pharmrev.120.000186
Timo W. M. De Groof
In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium (T.W.M.D.G.); Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom (E.G.E., J.H.S.); Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (M.S., R.H., M.J.S.); and QVQ Holding B.V., Utrecht, The Netherlands (R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Timo W. M. De Groof
Elizabeth G. Elder
In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium (T.W.M.D.G.); Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom (E.G.E., J.H.S.); Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (M.S., R.H., M.J.S.); and QVQ Holding B.V., Utrecht, The Netherlands (R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Siderius
In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium (T.W.M.D.G.); Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom (E.G.E., J.H.S.); Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (M.S., R.H., M.J.S.); and QVQ Holding B.V., Utrecht, The Netherlands (R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raimond Heukers
In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium (T.W.M.D.G.); Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom (E.G.E., J.H.S.); Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (M.S., R.H., M.J.S.); and QVQ Holding B.V., Utrecht, The Netherlands (R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raimond Heukers
John H. Sinclair
In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium (T.W.M.D.G.); Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom (E.G.E., J.H.S.); Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (M.S., R.H., M.J.S.); and QVQ Holding B.V., Utrecht, The Netherlands (R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine J. Smit
In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium (T.W.M.D.G.); Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom (E.G.E., J.H.S.); Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (M.S., R.H., M.J.S.); and QVQ Holding B.V., Utrecht, The Netherlands (R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunnar Schulte
Roles: ASSOCIATE EDITOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Pharmacological properties of human herpesvirus–encoded GPCRs. Overview of the different viral GPCRs (colored GPCRs in the middle) encoded by the herpesviruses HCMV (HHV-5), HHV-6, HHV-7, EBV, or KSHV; their known ligands (top); and interacting G proteins (bottom). Their closest human chemokine homolog and the percentage of total homology are depicted. For each vGPCR, known signaling properties (constitutive or ligand-dependent) have been annotated.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Major signaling pathways activated by human herpesvirus–encoded GPCRs in different disease settings. (A) Overview of the different (proliferative) signaling pathways activated by US28 (yellow arrows), UL33 (dark yellow arrows), ORF74 (pink arrows), and BILF1 (blue arrows) in cancer cells. Activation of some of these pathways results in the activation of cyclooxygenase 2 (COX2) and secretion of IL-6, PGE2, and VEGF. Secreted IL-6 activates the IL-6 receptor [consisting of the IL-6 receptor subunit (IL6R) and glycoprotein 130 (gp130)] . Activation of the IL-6 receptor results in the stimulation of the Janus kinase 1 (JAK1)-STAT3 pathway, leading to a feed-forward loop. Activation of these pathways contributes to several cancer hallmarks, including sustained proliferative signaling, tissue invasion, angiogenesis, and immune evasion. (B) Binding of CCL5 to US28 activates several pathways that result in smooth muscle cell migration in cardiovascular diseases. CCL5-mediated activation of US28 stimulates the Rho-associated protein kinase (ROCK) pathway and mitogen-activated protein kinase (MAPK) pathway and the formation of Src-mediated focal adhesion kinase (FAK) complexes, resulting in cytoskeletal changes, cell detachment, and subsequent cell migration. (C) US28 suppresses the major immediate early promotor (MIEP) and subsequent immediate early (IE) gene expression in early myeloid cells. US28 attenuates several pathways, including the CREB, activator protein 1 (AP-1) (via c-fos), and nuclear factor-κB (NF-κB) pathway. CREB-mediated signaling is inhibited by attentuation of the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, mitogen- and stress-activated kinase (MSK) 1 and CREB. By activation of the STAT3-inducible nitric oxide synthase (iNOS) pathway, US28 activation leads to increased nitric oxide (NO) levels, resulting in suppression of the MIEP. By suppression of MIEP, no IE expression is observed, resulting in a latent infection in early myeloid cells.

Tables

  • Figures
    • View popup
    TABLE 1

    Overview of the role of vGPRs in a viral setting

    vGPCR (Virus and Lytic Expression Kinetics)Role in Lytic InfectionRole in Latent InfectionRole in Dissemination/Immune EvasionOrthologs
    UL33 (HCMV late) (Davis-Poynter et al., 1997)Dispensable (Margulies et al., 1996) but enhances spread in multistep growth analyses (van Senten et al., 2020a); constitutive signaling (Casarosa et al., 2003a)Expression detected but no role established (Cheng et al., 2017)Murine and rat models suggest roles in replication in salivary gland, latency, and dendritic cell trafficking (Frank et al., 2019)Murine - M33 rat - R33
    UL78 (HCMV early) (Wagner et al., 2012)Dispensable (Michel et al., 2005) but important for entry into epithelial cells and replication in epi/endothelial cells (O’Connor and Shenk, 2012)Expression detected but no role established (Cheng et al., 2017)Murine and rat models suggest importance in replication in specific cell types in vivo (Oliveira and Shenk, 2001; Kaptein et al., 2003)Murine - M78 rat - R78
    US27 (HCMV late) (Vieira et al., 1998; Chambers et al., 1999; Margulies and Gibson, 2007)Important for extracellular spread (O’Connor and Shenk, 2011); promotion of cell growth and survival (Tu and Spencer, 2014)Expression not detected (Cheng et al., 2017; Shnayder et al., 2018)Highly conserved but in vivo role unclear (Stegman and Margulies, 2017; Frank et al., 2019)Present in primate CMVs but not rodent CMVs (Alcendor et al., 2009)
    US28 (HCMV early) (Vieira et al., 1998)Dispensable (Vieira et al., 1998; Humby and O’Connor, 2015); enhances infection of epithelial cells and smooth muscle cells (Noriega et al., 2014; Lollinga et al., 2017); constitutive and ligand-induced signaling (Krishna et al., 2018)Required for latency in in vitro models (Humby and O’Connor, 2015; Krishna et al., 2017a; Zhu et al., 2018); required for reactivation in humanized mice (Crawford et al., 2019)Induces cell migration and adhesion (Melnychuk et al., 2004; Vomaske et al., 2009; Hjorto et al., 2013; Wu and Miller, 2016; Farrell et al., 2018; Aslam et al., 2019); chemokine sink (Randolph-Habecker et al., 2002); myeloid differentiation (Zhu et al., 2018; Crawford et al., 2019)Present in primate CMVs but not rodent CMVs (Alcendor et al., 2009); five rhesus CMV US28 homologs characterized
    U12 (HHV-6A/B late) (Isegawa et al., 1998)Ligand-induced signaling (Isegawa et al., 1998); likely dispensable for viral replication (Dominguez et al., 1999)UnknownUnknownHomologs not functionally characterized
    U51 (HHV-6A/B early) (Menotti et al., 1999)Enhances viral replication (Zhen et al., 2005)UnknownLeukocyte migration/immunomodulation (Catusse et al., 2008)Homologs not functionally characterized
    U12 (HHV-7)Ligand-induced signaling (Nakano et al., 2003; Tadagaki et al., 2005)UnknownUnknownHomologs not functionally characterized
    U51 (HHV-7)Ligand-induced signaling (Tadagaki et al., 2005)UnknownUnknownHomologs not functionally characterized
    BILF1 (EBV early)Immune evasion (cell intrinsic and extrinsic) (Arfelt et al., 2015; Morales-Sánchez and Fuentes-Panana, 2018) not required for lytic replication (Zuo et al., 2011)Expressed at low levels (Tierney et al., 2015)Likely immune evasion including evasion of cytotoxic T-cell recognitionBILF1 homologs characterized in primate lymphocryptoviruses (Spiess et al., 2015a)
    ORF74 (KSHV early) (Chiou et al., 2002)Necessary for efficient lytic replication (Sandford et al., 2009)Expression kept at low levels (Vischer et al., 2014); possible reactivation from latency (Chen et al., 2009; Sandford et al., 2009)Murine models indicate important roles in reactivation from latency (Moorman et al., 2003; López-Rodríguez et al., 2019)MHV68 ORF74 (Virgin et al., 1997)
    • View popup
    TABLE 2

    Overview of US28-targeting and modulating agents

    Molecule ClassMolecule Name/ScaffoldMode of ActionInfection StateIn Vitro/In VivoFunctional EffectReference
    Small moleculePiperazinyldibenzothiepins; cinchonine derivates; cinchonidines derivates; arylamines; benzamidesAntagonists—In vitroLigand blockingVischer et al. (2014)
    Methiothepin; Octoclothepin; S-(−)-IodobenzamideAntagonist/partial inverse agonist—In vitroLigand blocking and partial inhibition of US28 constitutive activityVischer et al. (2010)
    VUF2274Antagonist/full inverse agonistLatent infectionIn vitroFull reactivation of latently infected cells resulting in T-cell–mediated cell deathCasarosa et al. (2003b); Krishna et al. (2017a)
    Derivates of flavonoids; biphenyl amides; CX3CR1 antagonists; VUF2274Agonist; antagonist; inverse agonist—In vitroLigand blocking/enhanced US28 signaling/partial inhibition of US28 constitutive activityKralj et al. (2011), (2013), (2014); Lückmann et al. (2017); Amărandi et al. (2018)
    NanobodyUS28-NbAntagonistCancer settingIn vitroLigand blockingHeukers et al. (2018)
    Bivalent US28-NbAntagonist/partial inverse agonistCancer settingIn vitro/in vivoPartial inhibition of US28-mediated enhanced glioblastoma tumor growthHeukers et al. (2018)
    VUN100-PSAntagonist/photosensitizer-induced cell deathCancer settingIn vitroSelective killing of US28-expressing glioblastoma cellsDe Groof et al. (2019b)
    Toxin-coupled chemokineF49A-FTPToxin-induced cell deathLytic infectionIn vitro/in vivoSelective killing of HCMV-infected cellsSpiess et al. (2015b)
    Latent infectionIn vitroKrishna et al. (2017b)
PreviousNext
Back to top

In this issue

Pharmacological Reviews: 73 (2)
Pharmacological Reviews
Vol. 73, Issue 2
1 Apr 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Viral G Protein–Coupled Receptors: Attractive Targets for Herpesvirus-Associated Diseases
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Review ArticleReview Article

Viral GPCRs as Attractive Targets

Timo W. M. De Groof, Elizabeth G. Elder, Marco Siderius, Raimond Heukers, John H. Sinclair and Martine J. Smit
Pharmacological Reviews April 1, 2021, 73 (2) 828-846; DOI: https://doi.org/10.1124/pharmrev.120.000186

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Review ArticleReview Article

Viral GPCRs as Attractive Targets

Timo W. M. De Groof, Elizabeth G. Elder, Marco Siderius, Raimond Heukers, John H. Sinclair and Martine J. Smit
Pharmacological Reviews April 1, 2021, 73 (2) 828-846; DOI: https://doi.org/10.1124/pharmrev.120.000186
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • I. Family of Viral G Protein–Coupled Receptors
    • II. Viral G Protein–Coupled Receptors in a Viral Setting
    • III. Role of Viral G Protein–Coupled Receptors in Disease
    • IV. Viral G Protein–Coupled Receptor–Targeting Modulators and Therapeutics
    • V. Concluding Remarks and Future Perspectives
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Modeling Pharmacokinetic Natural Product–Drug Interactions
  • Pharmacological Targeting the Complement System
Show more Review Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics